[C:1]([C:3]1[CH:4]=[C:5]([CH:25]=[CH:26][C:27]=1[O:28][C:29]1[CH:34]=[CH:33][C:32]([C:35]#[N:36])=[C:31]([F:37])[CH:30]=1)[CH2:6][O:7][C:8]1[CH:9]=[C:10]2[N:17](C(OC(C)(C)C)=O)[CH2:16][CH2:15][N:11]2[C:12](=[O:14])[N:13]=1)#[N:2]>C(Cl)Cl.C(O)(C(F)(F)F)=O>[C:1]([C:3]1[CH:4]=[C:5]([CH2:6][O:7][C:8]2[CH:9]=[C:10]3[NH:17][CH2:16][CH2:15][N:11]3[C:12](=[O:14])[N:13]=2)[CH:25]=[CH:26][C:27]=1[O:28][C:29]1[CH:34]=[CH:33][C:32]([C:35]#[N:36])=[C:31]([F:37])[CH:30]=1)#[N:2]Prepared in a manner similar to that described for E60 using tert-butyl 7-((3-cyano-4-(4-cyano-3-fluorophenoxy)benzyl)oxy)-5-oxo-2,3-dihydroimidazo[1,2-c]pyrimidine-1(5H)-carboxylate (70 mg, 0.139 mmol) in DCM (4 mL) and TFA (0.5 mL).
読み込み中…